Table 4.

Data of 6-year progression according to medication, motor symptoms, and NMSs.

	Test 1	Test 2	Changing ratio	P values
UPDRS PART III	22.76	31.73	39%	0.000*
LED-DA	96.6(12.7%)^	176.64(14.7%)^	83%	0.000*
Levodopa	486.12(63.8%)^	800.75(66.7%)^	65%	0.000*
LED-total	762.05	1200.47	58%	0.000*
Total score of NMSS	34.58	48.09	39%	0.008*
Cardiovascular	2.57	1.16	-55%	0.007*
Sleep/Fatigue	6.78	7.28	7%	0.837
Mood/cognition	6.51	12.25	88%	0.017*
Perceptual problems/hallucination	0.96	1.36	42%	0.306
Attention/memory	3.87	5.24	35%	0.174
Gastrointestinal	3.34	7.54	126%	0.000*
Urinary	5.58	7.6	36%	0.142
Sexual function	2.57	0	-100%	0.000*
Miscellaneous	3.75	5.66	51%	0.010*

UPDRS unified Parkinson’s disease rating scale; LED levodopa equivalent dosage; DA dopamine agonist.

^The percentage in parentheses is the ratio of the LED of a DA or levodopa to the total LED.

*P values < .017 indicates indicated significance by Wilcoxon signed-rank test.